title: What common biomarkers characterize a triple-negative profile in breast cancer?
abstract: Triple-negative breast cancers are not a homogeneous subgroup. There is substantial intra-subgroup diversity in tumor biology, prognosis and treatment sensitivity. Then, these triple-negative phenotype (TNP) groups, having specific features, can be again divided into subclasses based on an added immunohistochemical markers. The challenge in treating TNP breast cancers is that they are not responsive to antiestrogens or trastuzumab secondary to negative receptor status, and as a result have a poor prognosis. Therefore, the presence or absence of supplementary markers could help predict which therapies are best suited for patients based on the pattern that their disease markers show. In this review, we will recapitulate the major supplementary biomarkers related to triple-negative breast cancer, which could give new therapeutic options.
authors: Molecular and Cellular Diagnosis Processes, Centre of Biotechnology of Sfax, University of Sfax, Route Sidi Mansour, Po Box 1177, 3018 Sfax, Tunisia; Department of Pathology, Habib Bourguiba hospital, Sfax, Tunisia.
authors: I
authors: I
authors: Kallel
authors: Molecular and Cellular Diagnosis Processes, Centre of Biotechnology of Sfax, University of Sfax, Route Sidi Mansour, Po Box 1177, 3018 Sfax, Tunisia.
authors: M
authors: M
authors: Rebaï
authors: Department of Pathology, Habib Bourguiba hospital, Sfax, Tunisia.
authors: A
authors: A
authors: Khabir
authors: Molecular and Cellular Diagnosis Processes, Centre of Biotechnology of Sfax, University of Sfax, Route Sidi Mansour, Po Box 1177, 3018 Sfax, Tunisia. Electronic address: ahmed.rebai@cbs.rnrt.tn.
authors: A
authors: A
authors: Rebaï
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000188:drug therapy / Q000208:ethnology; D018275:Carcinoma, Lobular / Q000737:chemistry* / Q000188:drug therapy / Q000208:ethnology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D019398:Genes, BRCA1; D018773:Genes, erbB-1; D016158:Genes, p53; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000032:analysis*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D011944:Receptors, Androgen / Q000032:analysis; D012680:Sensitivity and Specificity; D064726:Triple Negative Breast Neoplasms / Q000737:chemistry* / Q000145:classification / Q000188:drug therapy / Q000208:ethnology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D014408:Biomarkers, Tumor; C497483:CD44 protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018960:Hyaluronan Receptors; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D011944:Receptors, Androgen; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Biomarkers; Biomarqueurs; Breast cancer; Cancer du sein; Profil triple négatif; Prognosis; Pronostic; Triple-negative profile